Contribute Try STAT+ Today

WASHINGTON — The pharmaceutical industry has sparred with President Trump for four years over drug pricing. Now it’s taking its biggest gamble yet: calling the president’s bluff.

The most brazen move came this week: Unlike most CEOs, who jump at the chance to visit the White House, pharmaceutical executives — newly empowered by their high-profile efforts to respond to the coronavirus and fed up with President Trump’s repeated threats — responded to his latest invitation with open contempt.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Trump wants to end the free ride other countries have been taking on our drug expertise. This is a good thing.

Comments are closed.